



Universiteit
Leiden
The Netherlands

Regulation of inflammation in uveal melanoma

Souri, Z.

Citation

Souri, Z. (2021, September 14). *Regulation of inflammation in uveal melanoma*. Retrieved from <https://hdl.handle.net/1887/3210126>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3210126>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <https://hdl.handle.net/1887/3210126> holds various files of this Leiden University dissertation.

Author: Sour, Z.

Title: Regulation of inflammation in uveal melanoma

Issue Date: 2021-09-14

Stellingen behorend bij het proefschrift getiteld

Regulation of Inflammation in Uveal Melanoma

1. The genetic evolution in uveal melanoma upregulates the NFkB signaling pathway and induces inflammation (*This Thesis*).
2. Chemotherapeutic drugs which target epigenetic regulators may impact immunotherapy in uveal melanoma (*This Thesis*).
3. Tumour-infiltrating leukocytes influence the chromatin architecture in uveal melanoma (*This Thesis*).
4. BAP1 regulates a network of miRNAs, with both pro- and anti-inflammatory capacities. (*This Thesis*).
5. Targeting LAG3 with monoclonal antibodies may revive the immune surveillance against uveal melanoma cells (*This Thesis*).
6. The gene and chromosomal aberrations found in monosomy 3/BAP1 loss uveal melanoma create an immunosuppressive microenvironment (*I.H.G. Bronkhorst, Invest Ophthalmol Vis Sci, 2012*).
7. Inflammation in cancer is a wound that never heals (*H.F. Dvorak, N Engl J Med, 1986*).
8. Immuno-editing of the primary tumour selects the best colony for dissemination (*J.Y. Niederkorn, Prog Retina Eye Res, 2009*).
9. Histone deacetylase inhibitors could increase the efficacy of immunotherapy in cancers (*M. de Lourdes Mora-García, J Transl Med, 2006*).
10. If you're brave enough to start, you're strong enough to finish (*G.R. Blair, 2018*).